PR Newswire
April 1, 2020
BIOMOLECULAR THERAPY VITORGAN
JOINING FORCES, WORLDWIDE
Life Valley Group Medical Expert Team
Miami, FL., April 1, 2020 /PRNewswire/ --
As doctors worldwide work tirelessly in the fight against multiple incurable diseases, Prof. Dr. Jiren Zhang Ph.D., director of the Department of Oncology, Zhejiang Hospital Southern Medical University, Dr. Med Karl Georg Theurer, CEO de vitOrgan Arzneimittel GmbH, Prof. Josephson, a quantum scientist and Nobel laureate at the University of Cambridge, UK, Prof. Dr. Dr. George Birkmayer, NADH Handels GmbH CEO, Austrian Birkmayer Anti-anging Research Institute, Prof. Rafael Contreras- Galindo Ph.D., Mayo Clinic, University of Minnesota, The Hormel Institute, USA and Dr. David Contreras director and specialist on Bimolecular therapy for the Americas, joined forces to conduct a fruitful research on the vitOrgan therapy, which is valued as a revolutionary biotechnology by the American Journal of Medicine.
The result of this research resulted in successfully publishing a book of 453 pages called “vitOrgan Targeting Cell Molecular Therapy” with all the extensive data and cases found during the worldwide investigation.
vitOrgan Bimolecular therapy uses cell molecules for anti-aging, since the 1965s in European countries.
Since 1965, vitOrgan has been widely used in many European countries and became the first popular brand of anti-aging, funcional sports and general medicine in Europe.
The research found that cluster analysis through biomedical informatics techniques suggests cytokines of vitOrgan is a positive influences in cell biomedical regulation, including positive regulations of insulin-like growth factor receptor signaling pathway, cell proliferation, cell division, cell growth, ERK1, and ERK2 cascade, bone mineralization, epithelial cell proliferation, phosphatidylinositol 3-kinase signaling, protein kinase B signaling, glucose import, MAPK cascade, oust blast, differentiation pathway-restricted SMAD protein phosphoryl, cAMP metabolic process, tyrosine phosphorylation of Stat1 protein, participating immune response, proteoglycan biosynthetic process, inflammatory response, defense response to virus, chemokine-mediated signaling pathway, angiogenesis, growth factor activity, insulin secretion, DNA replication, lymphocyte chemotaxis, peptide catabolic process, endothelial cell apoptotic process and many other cell molecular activities. Our results confirm the great potential of vitOrgan bimolecular therapy as a clinical relevant therapeutic strategy.
Moreover, antiallergic therapy with vitOrgan is currently an effective method for hypersensitivity of the immune system demonstrated by F. Heiss of the University Medical Center Hamburg-Eppendorf (UK8) (8).
Also, biomolecular therapy with vitOrgan is currently and effective method for immunotherapy in cancer treatments. It address the negative effects of Chemotherapy, stimulates immune function of T-cells and macrophages, helps with the differentiation and development of reactive T-cells: CD4,CD8, natural killer cells, as demonstrated by Prof. Rafael Contreras- Galindo Ph.D., Mayo Clinic, University of Minnesota, The Hormel Institute USA
VITORGAN TARGETING
CELL MOLECULAR THERAPY
DR. Med. Karl Georg Theurer
DR. David Contreras
Life Valley Group Medical Expert Team specializes on vitOrgan as live or fresh cell therapy as not only used in adjuvant treatment of daily diseases such as asthma, bronchitis, fatigue syndrome, sinusitis, immunodeficiency, diabetes mellitus, cancer, cardiovascular and cerebrovascular diseases, but also in the prevention and treatment of chronic motor diseases, osteoarthritis, cartilage injury, intervertebral disc disease, etc.
This bimolecular therapy, is widely used in the field of anti-aging, preventive medication to reduce the risk of diseases. It has been jointly recommended by the three major anti-aging institutions in the world: the capital of Füssen, Germany, the green grasslands of Montreux, Switzerland, and Quiet Harbor, Switzerland.
Stars and politicians from various countries like German Chancellor Konrad Adenauer and Germany’s current chancellor Angela Merkel, have chosen to use vitOrgan bimolecular therapy and products to promote health and prevent various diseases, creating miracles and myths in the history of not only the German medical and health industry but also worldwide.
BIOMOLECULAR THERAPY VITORGAN
JOINING FORCES, WORLDWIDE
BIOMOLECULAR THERAPY VITORGAN
JOINING FORCES, WORLDWIDE
BIOMOLECULAR THERAPY VITORGAN
JOINING FORCES, WORLDWIDE
Biomedical Press Release
April 1, 2020
VITORGAN TARGETING CELL
MOLECULAR THERAPY BOOK
Biomedical Press Release
For a better understanding and scientific use of vitOrgan Targeting Cell Molecular Molecular Therapy, this book introduces the cellular and molecular changes of organ aging, circulatory system, respiratory system, nervous system system and other aging processes, and the aging and chronic diseases
"Relationships, Chronic Disease Risk Factors", a brief introduction to the life science assessment technique.
This book systematically discusses the source, production and quality control of Vital target cell molecules, and researches on the molecular mechanism of cell molecules ~, shows the signal transduction pathways and regulatory paths of some vitOrgan target cell molecules, and the range of methods, and use of targeted cell molecular therapy in anti-aging, functional maintenance, and adjuvant treatment of chronic diseases, as well as clinical case reports used by European and American clinicians.
April 1, 2020
This book can meet the needs of readers at different levels, and can be used as a scientific reading for cell and molecular therapy, as well as a reference for clinicians and researchers.
vitOrgan Targeted Cell Molecular Therapy / Zhang Jiren,
Dr. Med. Karl Georg Theurer (Germany), editor-in-chief of Dr. Dnvid Contreras (Colombia), 1 Hong Kong: Hong Kong Press, 2019. 8 ISBN 978-988-74043-0-9 1.0 push ... I.O Zhang ②K.G. T 3D. C ... II. O Cell Molecular Therapy 1 Research and Application N. Brief Introduction OR730.5
VITORGAN THERAPY
SCIENTIFIC RESEARCH
